Indeed, fibrates (activators of PPAR α and beta-δ) and thiazolidinediones (TZD; PPAR γ ligands) are used for the treatment of dyslipidemia and diabetes, respectively [25,26,85]. This evidence concerns the gene PPARA and metabolic syndrome.